Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in advanced or metastatic biliary tract cancer
NCT04156958Phase 2
Key facts
- Status
- Unknown
- Start
- Dec 2019
- Primary completion
- Sep 2021
- Countries
- 1
- Sponsor
- Sichuan University
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Drugs
- fruquintinib
- Conditions
- biliary tract adenocarcinoma
01
Overview
Phase 2, open-label trial of fruquintinib in biliary tract adenocarcinoma, sponsored by Sichuan University. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Adults with advanced or metastatic biliary tract adenocarcinoma who failed first-line chemotherapy (gemcitabine, platinum/S-1, and albumin paclitaxel) with ECOG PS 0-1 and adequate organ function.
04
Registry description
The prospective, multicenter, single-arm design study is to evaluate the efficacy and safety of fruquintinib for patients with advanced or metastatic biliary tract adenocarcinoma who failed first-line chemotherapy with gemcitabine, platinum/S-1, and albumin paclitaxel.
Beyond the preview
Go deeper on NCT04156958.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156958.